



TO: Consensus Standards Approval Committee (CSAC)

FR: Helen Burstin, Chief Scientific Officer
Marcia Wilson, Senior Vice President, Quality Measurement

RE: Appeal of Measures for the Cost and Resource Use Standing Committee Ad Hoc Review of the Conceptual and Empirical Analysis of Sociodemographic Variables and Payment Outcomes

DA: June 29, 2016

ACTION REQUIRED

The CSAC will provide guidance on appeals of the following measures:

- #2431: Hospital-level, risk-standardized payment associated with a 30-day episode-of-care for Acute Myocardial Infarction (AMI) (CMS/Yale)
- #2436: Hospital-level, risk-standardized payment associated with a 30-day episode-of-care for Heart Failure (HF) (CMS/Yale)
- #2579: Hospital-level, risk-standardized payment associated with a 30-day episode of care pneumonia (CMS/Yale)

BACKGROUND

The National Quality Forum (NQF) has received two appeals of its endorsement of the acute myocardial infarction (AMI) (NQF # 2431), heart failure (HF) (NQF #2436) and pneumonia (NQF #2579) 30-day episode-of-care payment measures. The Cost and Resource Use Standing Committee has deliberated on the scientific properties of these measures extensively and had made recommendations to CSAC and the Board prior to the start of the trial period, and, upon request from the Board, re-examined the measures using the sociodemographic (SDS) trial period guidance. The Cost and Resource Use Standing Committee reviewed analyses from the developer and recommended the measures continue to be endorsed without the inclusion of SDS factors in their risk adjustment models. The decision was approved by the CSAC and ratified by the Executive Committee of the NQF Board of Directors. Appeals of this decision were submitted by the American Medical Association (AMA) and jointly by four hospital associations, the American Hospital Association, the Federation of American Hospitals, the Association of American Medical Colleges, and America's Essential Hospitals. NQF has responded to the appellants and convened the appellants with representatives from the Centers for Medicare and Medicaid Services (CMS) and the measure developer (Yale/CORE).

SUMMARY OF APPEAL AND NQF RESPONSE

SDS Trial Period Concerns

- The appellants raise concerns about the testing of race as a possible factor for inclusion in the risk adjustment model of the measures. In particular the appellants raise two concerns about the developer's use of race:

- The appellants believe the developer did not provide an adequate conceptual basis for the use of race as a variable and did not explain why it was appropriate to aggregate individuals into “black or non-black;”
- The developer tested only one other SDS adjustment variable (dual eligibility). The appellants note the SDS Expert Panel stated that race should not be used as a proxy for SES; rather race is confounded by SES. The appellants believe the developers did not test enough variables to unmask any conceptual relationship and that the relationship between race and the measures’ outcomes are likely to remain confounded.
- NQF Response:
 - Guidance was provided to the measure developers and the Standing Committee based on the recommendations of the SDS expert panel that race should not be used as proxy for SDS and should not be used in adjustment unless there is a clear conceptual rationale.
 - During its May 21, 2015 webinar to review the developer’s conceptual analysis, the Cost and Resource Use Standing Committee raised concerns about the inclusion of race as a variable. The Committee believed that further literature review was needed to determine the within and between effects of race on hospital performance. Some members strongly suggested that between and within hospital differences should be a lens through which this information should be analyzed.
 - In a memo dated October 5, 2015, the developer summarizes the results of their expanded literature search. The developer found that most studies use race and their independent variable with less attention to income or other measures of poverty. The developer concluded that the literature demonstrates that both within and between hospital differences in outcomes among racial/ethnic groups can be partially explained by the use of lower quality hospitals by minorities.
 - During the May webinar, the Standing Committee raised similar concerns to the appellants about the aggregation of racial categories. However, in the October 5 memo, the developer confirms that while they considered creating categorizations of black/white/other or black/white/other/Hispanic, data from CMS suggests that black and white race are the only categories with both high sensitivity and specificity in the Beneficiary Race Code variable.
 - Race was not included as a variable in the final risk adjustment model; rather it was only explored by the developer.
 - NQF agrees with the appellants that race should not be used as proxy for SES. This guidance was explicitly stated in the SDS Expert Panel’s final report. The Disparities Standing Committee is currently examining this issue and is in the process of providing additional guidance to measure developers and NQF Standing Committees about the use of race as a variable in risk adjustment models.
- The appellants note that the Cost and Resource Use Standing Committee urged the measure developer to explore in their conceptual model community and environmental factors, and to separate patient and community-level resources.
- NQF Response:

- During its October 27, 2015 webinar to review the developer’s empirical analysis, the Committee had extensive discussion about the inclusion of community-level factors into the risk-adjustment model given the inclusion of a 30-day post discharge period in the episode. The Committee acknowledged that for some of the post-hospitalization services, the community context is a critical variable and that these factors may or may not be fully captured by the patient-level SDS adjustment.
 - The developers expressed interest in potentially considering these factors in the model, but sought Committee input and recommendations on how to approach this.
- The developer did not sufficiently explore the variables included in the conceptual model. Additionally, the appellants raise concerns that the developers did not perform the analyses requested by the Standing Committee. In particular, the developer did not expand the analyses to the nine-digit zip code level and did not include Low Income Status along with the Medicaid enrollment/dual status variable.
- NQF Response:
 - The developer expanded the conceptual model in response to the Cost and Resource Use Standing Committee’s concerns. The CMS/Yale team revised the model to broaden the scope of community-level factors included in the model. In doing so, they updated the pre-admission and post discharge phases of the conceptual model to capture the many patient and community factors that reflect differential impact of SDS on episode of care payments. The developer also revised the model to reflect “patient factors” rather than “patient behaviors.” Patient factors included variables such as using services provided and adherence to care plan. Community factors included variables such as lack of community services and lack of social supports/caregiver. Finally, the model also was reoriented to capture the potential pathways by which low SDS may impact the care provided to patients. Details of the final memo can be found in the developer’s October 5 memo.
 - The Cost and Resource Use Standing Committee noted significant gaps in the literature specific to the impact of SDS on cost, utilization, or payment outcomes. Specifically, the Committee questioned whether the use of standardized payments based on diagnosis-related groups may mitigate the relationship between SDS and costs.
 - In the October 5 memo, the developer clarified they chose to use the Dual Status variable because it best reflected those with the lowest income.
- The appellants raise concerns about the implementation of the trial period. Specifically the appellants have concerns about:
 - The guidance provided to Standing Committees on the selection and testing of SDS variables.
 - Consensus Standards Approval Committee (CSAC) approval of the revised measure evaluation criteria.
- NQF Response:
 - NQF recognizes that the SDS trial period marks a significant change the Consensus Development Process. NQF staff has worked to provide guidance to measure

developers, Standing Committees, and the public to educate them on the input of the SDS expert panel and on how measures should be reviewed during the trial period.

- Web meetings have been held with measure developers and Standing Committees are briefed on the changes during their orientation and Question and Answer calls. NQF will work to improve the clarity and breadth of the educational materials and opportunities provided to developers, Standing Committees, and the public.
- However, NQF maintains a non-prescriptive approach to the selection and testing of variables included in risk adjustment models. NQF does not require that certain variables be tested and does not set requirements around the inclusion of any specific variables. Similarly NQF does not set certain “cut-points” for the statistical testing of a risk adjustment model. The evaluation of the model is left to the Standing Committee reviewing the measure. This approach applies to both clinical and SDS variables.
- The Disparities Standing Committee is charged with evaluating the trial period. Results to date were presented to the Disparities Standing Committee during their April 26, 2016 webinar. The Committee is currently drafting additional guidance based on the findings and challenges of the trial period to date. This guidance will be provided to the Standing Committees, developers, and public by early summer 2016.
- Updates to the measure evaluation criteria were made as part of the CSAC’s approval of the SDS Expert Panel’s recommendations during its July 9-10, 2014 meeting. Specifically, the Expert Panel’s Recommendation 4 revised the criteria. These recommendations passed with the consensus of the CSAC.

Insufficient Resolution of the Conditions of Endorsement

- The appellants raise concerns that the three conditions for endorsement have not been adequately met. First, the appellants raise concerns about the one-year look back assessment of unintended consequences of these measures in use.
- NQF Response:
 - There is general agreement that these measures need to be monitored as they are endorsed and implemented into federal quality initiative programs. These measures have been recently adopted for the Hospital Inpatient Quality Reporting program for FY 2016 (AMI) and FY 2017 (HF and pneumonia). NQF will need implementation data from CMS as experience with the measures has been demonstrated. The May 10 meeting will allow the appellants and CMS the chance to opportunities to develop a path forward on the look back period issue
- Secondly, the appellants raise concerns about the need to consider issues of attribution.
- NQF Response:
 - With funding from HHS, NQF has launched a project on attribution. The expert panel guiding this work includes representation from both hospitals and the American Medical Association to ensure attribution issues such as the ones illustrated by these measures are addressed. As part of this project, NQF will commission an environmental scan identify different attribution models and examine their strengths and weaknesses. The

environmental scan will be used as a foundation for establishing a set of principles and recommendations for applying the models within a complex healthcare delivery system. Throughout this project, NQF will solicit input from NQF's multi-stakeholder audience, including NQF membership and public stakeholders at key points throughout the project.

ADDITIONAL CONSENSUS BUILDING

In June 2016, NQF convened the appellants, CMS, Yale/CORE, the CSAC co-chairs, and one of the chairs of the Cost and Resource Use Standing Committee. The goal of this call was to foster a dialogue between the affected parties and to lay out potential options as the appeal is considered. During the call the appellants asked for clarification for the conceptual basis for the expected effect of adjustment. Yale/CORE agreed to provide a clearer conceptual analysis and to perform additional empirical analyses to examine the impact of SES factors at the nine-digit zip code level to address the concerns raised by the appellants.

NEXT STEPS

NQF will convene the Cost and Resource Use Standing Committee to review Yale's additional analyses and provide input to CSAC. CSAC will review this input and consider the appeal during their August meeting.



Review of Appeals: Cost and Resource Use Ad Hoc Review Measures

July 13, 2016

Cost and Resource Use Ad Hoc Review Appeals

- Appeals were submitted on the continuing endorsement of:
 - #2431: *Hospital-level, risk-standardized payment associated with a 30-day episode-of-care for Acute Myocardial Infarction (AMI) (CMS/Yale)*
 - #2436: *Hospital-level, risk-standardized payment associated with a 30-day episode-of-care for Heart Failure (HF) (CMS/Yale)*
 - #2579: *Hospital-level, risk-standardized payment associated with a 30-day episode of care pneumonia (CMS/Yale)*

Cost and Resource Use Ad Hoc Review Appeals

- These measures were endorsed just prior to the start of the SDS trial period.
- Upon the request of the NQF Board these measures were re-examined for the potential need for SDS adjustment.
- The Cost and Resource Use Standing Committee review analyses from the developer and recommended these measures continue to be endorsed without the inclusion of SDS factors in their risk adjustment models.
- This decision was approved by CSAC and ratified by the Board Executive Committee.
- Appeals were submitted by the AMA and four hospital associations

Summary of Appeal: SDS Trial Period Concerns

- Testing of race as a possible risk adjustor:
 - *Developer did not provide an adequate conceptual basis for use of this variable.*
 - *The only other SDS variable tested was dual eligibility.*
- NQF Response:
 - *SDS Expert Panel provided guidance that race should not be used as a proxy for SDS.*
 - *Standing Committee raised concerns about the potential inclusion of race and asked for further literature review.*
 - *Race was not included in the risk adjustment model; it was only explored by the developer.*

Summary of Appeal: SDS Trial Period Concerns

- The Standing Committee requested that the developer explore community and environmental factors in their conceptual model and to separate patient and community level resources.
- NQF Response:
 - *Committee had extensive discussion about the inclusion of community-level factors into the risk-adjustment model given the inclusion of a 30-day post discharge period in the episode.*
 - *Developers expressed interest in considering these factors; sought Committee recommendations on how to do so.*

Summary of Appeal: SDS Trial Period Concerns

- The developer did not sufficiently explore the variables included in the conceptual model.
- The developer did not expand the analyses to the nine-digit zip code level and did not include Low Income Status along with the Medicaid enrollment/dual status variable.
- NQF Response:
 - *The developer expanded the conceptual model in response to the Cost and Resource Use Standing Committee's concerns.*
 - » The CMS/Yale team revised the model to broaden the scope of community-level factors included in the model.
 - » The developer clarified they chose to use the Dual Status variable because it best reflected those with the lowest income.
 - » CMS/Yale have performed additional analyses at the nine-digit zip code level. The Standing Committee will review these analyses and provide input to CSAC.

Summary of Appeal: SDS Trial Period Concerns

- The appellants raise concerns about the implementation of the trial period.
 - *The guidance provided to Standing Committees on the selection and testing of SDS variables.*
 - *Consensus Standards Approval Committee (CSAC) approval of the revised measure evaluation criteria.*
- NQF Response:
 - *NQF will work to improve the clarity and breadth of the educational materials and opportunities provided to developers, Standing Committees, and the public.*
 - *NQF maintains a non-prescriptive approach to the selection and testing of variables included in risk adjustment models.*
 - *The Disparities Standing Committee is currently drafting additional guidance based on the findings and challenges of the trial period to date.*
 - *Updates to the measure evaluation criteria were made during CSAC's July 9-10, 2014 meeting.*

Summary of Appeal: Insufficient Resolution of the Conditions of Endorsement

- The appellants raise concerns about the one-year look back assessment of unintended consequences of the use of these measures.
- NQF Response:
 - *These measures have been recently adopted for the Hospital Inpatient Quality Reporting program for FY 2016 (AMI) and FY 2017 (HF and pneumonia).*
 - *NQF will need implementation data from CMS as experience with the measures has been demonstrated.*

Summary of Appeal: Insufficient Resolution of the Conditions of Endorsement

- The appellants raise concerns about the need to consider issues of attribution.
- NQF Response:
 - *NQF has convened a multistakeholder committee to establish a set of principles and recommendations for applying attribution models.*

Additional Consensus Building

- NQF convened the appellants, CMS, Yale/CORE, the CSAC co-chairs, and one of the chairs of the Cost and Resource Use Standing Committee.
- The goal was to foster dialogue and lay out potential options as the appeal is considered.
- The appellants asked for clarification for the conceptual basis for the expected effect of adjustment.
- The developer agreed to perform additional analyses:
 - *Clarify conceptual basis*
 - *Examine the impact of SES factors at the nine-digit zip code level*

Next Steps

- The Cost and Resource Use Standing Committee will meet via webinar in July to review Yale's additional analyses and provide input to CSAC.
- CSAC will review this input and consider the appeal during their August meeting.